# Kaya Limited

May 30, 2022

To,
BSE Limited
Market Operations Department,
1st Floor, Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400001
BSE Scrip Code: 539276

National Stock Exchange of India Limited 'Exchange Plaza', 5<sup>th</sup> Floor, Plot No. C/1, G Block, Bandra Kurla Complex, Bandra(E), Mumbai 400051 NSE Symbol: KAYA

#### **Subject: Performance update**

Dear Sir/ Madam,

Please find enclosed performance update on the financial results of the Company for the quarter ended March 31, 2022.

Kindly take the above on record.

#### For Kaya Limited,

NITIKA

Digitally signed by NITKA SUNNY NINKA

SUNNY

NINKA

SUNNY

NINKA

SUNNY

NINKA

SUNNY

NINKA

SUNNY

NINKA

SUNNY

NINKA

SUNNY

NINKA

SUNNY

NINKA

SUNNY

NINKA

SUNNY

SUNN

Nitika Dalmia Company Secretary & Compliance Officer

Encl: A/a

Registered Office: Kaya Limited, Marks, 23/C, Mahal Industries Estate, Mahakali Caves Road, Near Paper Box Lane, Andheri (E), Mumbai 400 093. Tel.:91-22-66195000. Website: <a href="https://www.kaya.in">www.kaya.in</a>

CIN: L85190MH2003PLC139763



### DISCLAIMER

This investor presentation has been prepared by Kaya Limited ("Kaya") and does not constitute a prospectus or placement memorandum or an offer to acquire any securities. This presentation or any other documentation or information (or any part thereof) delivered or supplied should not be deemed to constitute an offer.

No representation or warranty, express or implied is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of such information or opinions contained herein. The information contained in this presentation is only current as of its date. Certain statements made in this presentation may not be based on historical information or facts and may be "forward looking statements", including those relating to the general business plans and strategy of Kaya, its future financial condition and growth prospects, future developments in its industry. These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results, opportunities and growth potential to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include but are not limited to risks with respect to its skin care and hair care business.

Kaya may alter, modify or otherwise change in any manner the content of this presentation, without obligation to notify any person of such revision or changes. This presentation cannot be copied and disseminated in any manner.


No person is authorized to give any information or to make any representation not contained in and not consistent with this presentation and, if given or made, such information or representation must not be relied upon as having been authorized by or on behalf of Kaya.

Note: The cut off period for all the details provided in the Investor presentation is till 31 March 2022



# TABLE OF CONTENTS

- FACT SHEET
- KAYA: A QUICK WALKTHROUGH
- KEY HIGHLIGHTS
- STRATEGIC PILLARS
- INITIATIVES WITH IMPACT
- FINANCIAL OVERVIEW



92 + CLINICS

31+ CITIES

4 COUNTRIES

Skin, Hair & Body SERVICES

60+ PRODUCTS

Over 100K KAYA SMILES MEMBERS

80%+
WOMEN
WORKFORCE

FACTS - Kaya India & Middle East




### Inclusive Beauty Brand for Life: Kaya


- An 18-year-old brand with services, products across 31+ cities, 4 countries. Services of laser hair reduction, brightening and pigmentation, antiageing, acne, hair care, body contouring, among others.
- Kaya provides services for customers from ages
   18+ to 70+
- Kaya is beauty without judgement it's about enabling every individual to choose their definition of beauty.

### 100+ MD Dermatologists : Largest Expert Pool

- Services and products designed in consultation with dermatologists at Kaya
- Kaya works with 100+ experienced dermatologists, who offer personalized solutions







# New Clinic Renovation

in Line with the new rebrand

- A more contemporary, simplistic yet stylized design grammar to accentuate Kaya's Inclusive Beauty Agenda: Beautiful is You
- Progressive improvement planned in clinic infrastructure across the 2 years
- 6 Clinics renovated over the last 2 quarters





### KAYA INDIA GROWTH

- Customer Count in Q4 FY22 grew by 3% over Q4 FY21
- Products Business grew by 12% in Q4 FY22 over Q4 FY21
- Laser Hair Reduction grew by
   5% over Q4 FY21, Hair Care
   grew by 10% over Q4 FY21

### KAYA MIDDLE EAST GROWTH

- New Customer count grew by 2% over Q4 FY21
- Body Solutions grew by 49% over Q4 FY21 & Hair Care by 20% same period
- Average Ticket size grew by 2% over Q4FY 21

### KAYA GROUP GROWTH

 Collection in Q4 FY22 grew by only 0.3% over Q4 FY21 due to the COVID impact.





# STRATEGIC PILLARS

- KAYA SMILES
- PRODUCTS
- SERVICES
- D2C
- CUTTING EDGE VERTICALS

# STRATEGIC

KAYA SMILES

SERVICES

**PRODUCTS** 

D2C

CUTTING EDGE VERTICALS



90% contribution to India's clinic collection



78% Net Revenue Contribution in India



**22%** Net Revenue Contribution in India




**5%** Net Revenue Contribution product in India



n **10%** Collection Contribution in Middle East

# KAYA SMILES LOYALTY PROGRAM

- Loyalty Program making India's beauty journey fulfilling and rewarding
- Contributing to 90% of India's Clinic collection in Q4 FY22
- Annual Retention of HNI customers (Platinum, Gold Elite, Gold) was at 78% vs FY 21
- High net worth Platinum customers contributing to 38% of India's Clinic collection in Q4 FY22





# **PRODUCT**


USP- Dermat Curated |60+ Strong Portfolio


- 22% of Kaya India's Collection
- Multichannel Presence across Clinics, E-Commerce, D2C
- Launch of Dermat backed New Products (last 2 quarters) high on efficacy: Retino Boost Serum, AHA BHAs and Super Hydrator, driving additional 10% of India's Product Business in Q4 FY22
- In-house R&D Lab leading Kaya's Innovation Journey

# **SERVICES**

Skin, Hair & Body Services 100+Dermats 92+ Clinics

- 78% of Kaya India's Revenue | 90% of Kaya Middle East Collections
- Launch of body contouring service Cool Sculpt to establish Kaya's credentials in Body in India
- Advanced Growth Factor based Platelet Rich Plasma (GFC-PRP) service for hair rejuvenation for faster results & higher efficacy in India
- Laser Hair Reduction Campaigns created to establish Kaya's turf as safe, efficacious, service to combat competition from at the home service providers In India
- Kaya Middle East's focus has been on the launch of the Body Contouring vertical which now contributes to 10% of the business and growing at a rapid rate






# D2C

Al Enabled Website | Driving Business Through Tech


- Launch of Al Powered site that aids in self diagnosis with product recommendations
- High Product Average Ticket Size on the website in line with Clinic Product Average Ticket Size



# NEW INITIATIVES

- Al Tool in Website
- Investment in New Service Technologies
- Dermat Forward New Product Launches
- Investment in tech core stack with

MS Dynamics 365



# DRIVING BUSINESS THROUGH TECHNOLOGY:

Kaya's first ever Al platform that enables customers to self - diagnose their skin to provide solutions online

App allows for Self Diagnosis using Al and leads to following outcomes:

- Product/service recommendations based on the diagnosis
- Enabling product sales

# Dermatology Technology based Services Launches

#### Laser Hair Removal in India

- 5% growth in Q4 FY22 vs. Q4 FY21
- 6 USFDA based machines introduced from South Korea

### Cool-Sculpt in India

4 Advanced Global New Machines for Body Contouring to strengthen Kaya's Body Services portfolio

# High-Intensity Focused Ultrasound in India

47% growth in FY Q422 vs. FY Q421 4 New Machines from South Korea for Skin Tightening, Lifting, Contouring

### Body Solutions in Middle East


49% growth in Body in Q4 FY22 over Q4FY21 Launch of Tru Sculpt Flex Addition of 3 more Cool Sculpt Machines

#### Hair Solutions in Middle East

20% growth in Hair Solutions in Q4 FY22 over Q4FY21

3 new services launched

# Crafting New Product Launches In line with Kaya's USP – Dermatology Forward





Kaya's data-centric approach to drive scientific decision making across functions

> **Building analytical business organization** based on tech



## KAYA GROUP HIGHLIGHTS


 Overall business was impacted in Jan 22 and Feb 22 due to COVID. March 2022 went back to pre-COVID level


### Kaya India (SSG)


- Collection in Q4 FY 22 declined by 2% over Q4 FY 21
- Customer count in Q4 FY 22 grew by 3% over Q4 FY 21
- Average ticket size in Q4 FY 22 declined by 5% over Q4 FY 21


### Kaya Middle East


- Collection in Q4 FY 22 declined by 1% over Q4 FY 21 at constant currency
- Customer count in Q4 FY 22 declined by 3% over Q4 FY 21
- Average ticket size in Q4 FY 22 grew by 3% as compared to Q4 FY 21
- Collection in Q4 FY 22 grew by 0.3% over Q4 FY 21
- Net Revenue in Q4 FY 22 declined by 6% over Q4 FY 21
- EBITDA of INR 3.8 crs (5% of NR) in Q4 FY 22, as compared to INR 19.1 crs (21% of NR) in Q4 FY21
- <u>PAT bei</u> at INR (41.3) crs (-50% of NR), as compared to INR (2.1) crs (-2% of NR) in Q4 FY21


















## KAYA INDIA HIGHLIGHTS

- Collection declined by 1% in Q4 FY 22 over Q4 FY 21
- Net Revenue in Q4 FY 22 declined by 1% over Q4 FY 21 on SSG basis
- Clinic Revenue in Q4 FY 22 declined by 4% over Q4 FY 21 on SSG basis
- Ecommerce Revenue in Q4 FY 22 grew by 14% over Q4 FY 21
- Ecommerce EBITDA of INR 1.7 crs (40% of NR), as compared to INR (0.2) crs (-6% of NR) in Q4 FY 21
- Kaya India EBITDA of INR 5.4 crs (14% of NR), as compared to INR 11.6 crs (28% of NR) in Q4 FY 21
- EBITDA margins in Q4 FY 22 are subdued as business was impacted in Jan 22 due to COVID.













# KAYA MIDDLE EAST HIGHLIGHTS

- Collection declined by 1% in Q4 FY 22 over Q4 FY 21 at constant currency
- Segments like Body Solutions grew by 49%, Hair Care grew by 21% and Anti-Ageing grew by 5% over Q4 FY 21
- Net Revenue declined by 9% in Q4 FY 22 over Q4 FY 21 at constant currency
- EBITDA of INR (1.6) crs (-4% of NR), as compared to INR 7.5 crs (15% of NR) in Q4 FY 21
- PAT bei of INR (32.8) crs (-73% of NR), as compared to INR (3.1) crs (-6% of NR) in Q4 FY 21









# FINANCIAL HIGHLIGHTS: Q4 FY22

Particulars -	Kaya India			Kaya Middle East			Kaya Group		
(INR crs)	Q4 FY22	Q4 FY21	Gr %	Q4 FY22	Q4 FY21	Gr %	Q4 FY22	Q4 FY21	Gr %
Collection	46.1	46.7	-1%	47.6	46.7	2%	93.7	93.4	0%
Net Revenue*	39.3	41.7	-6%	45.3	48.7	-7%	83.5	89.2	-6%
EBITDA	5.4	11.6	-54%	-1.6	7.5	-122%	3.8	19.1	-80%
% to NR	14%	28%		-4%	15%		5%	21%	
Operating Margin	(6.5)	3.4		(30.3)	(0.0)		(36.8)	3.4	-
% to NR	-16%	8%		-67%	0%		-44%	4%	
PAT bei	(8.5)	1.0		(32.8)	(3.1)		(41.3)	(2.1)	Ultra de la companya
% to NR	-22%	3%		-73%	-6%		-50%	-2%	
PAT aei**	(8.7)	1.2	11 11	(33.9)	(1.7)	ATTICE AND A STATE OF THE PARTY	(42.6)	(0.5)	
% to NR	-22%	3%	11 11	-75%	-4%		-51%	-1%	

Net Revenue declined by 6% over PY

EBITDA margin is 5% of NR as against 21% of NR in PY

Operating margin is -44% of NR as against 4% of NR in PY

PAT bei at -50% of NR, as against -2% of NR in PY

\* Net Revenue of Kaya Group excludes intercompany Transactions

\*\* PAT aei is PAT after other comprehensive income and noncontrolling interest

One time impact of INR 29.9 crs in Statement of Profit and loss includes clinic impairment of INR 15.4 crs and Goodwill impairment of INR 8.1 crs

# FINANCIAL HIGHLIGHTS: YTD MAR 22

Particulars -	Kaya India			Kaya Middle East			Kaya Group		
(INR crs)	YTD Mar 22	YTD Mar 21	Gr %	YTD Mar 22	YTD Mar 21	Gr %	YTD Mar 22	YTD Mar 21	Gr %
Collection	161.3	123.0	31%	194.6	165.9	17%	355.9	288.9	23%
Net Revenue*	140.9	117.1	20%	187.6	162.0	16%	324.0	275.0	18%
EBITDA	18.1	26.7	-32%	17.3	12.4	39%	35.4	39.1	-10%
% to NR	13%	23%		9%	8%		11%	14%	N
Operating Margin	(16.8)	(5.5)		(33.7)	(15.8)		(50.6)	(21.3)	
% to NR	-12%	-5%		-18%	-10%		-16%	-8%	
PAT bei	(25.5)	(14.1)		(42.5)	(23.3)		(68.0)	(37.4)	
% to NR	-18%	-12%		-23%	-14%		-21%	-14 <mark>%</mark>	
PAT aei**	(25.8)	(14.3)		(44.2)	(24.6)		(70.0)	(38.9)	
% to NR	-18%	-12%		-24%	-15%		-22%	-14%	

EBITDA margin is 11% of NR as against 14% of NR in PY

Operating margin is -16% of NR as against -8% of NR in PY

PAT bei at -21% of NR, as against -14% of NR in PY

\* Net Revenue of Kaya Group excludes intercompany Transactions

\*\* PAT aei is PAT after other comprehensive income and noncontrolling interest

One time impact of INR 29.9 crs in Statement of Profit and loss includes clinic impairment of INR 15.4 crs and Goodwill impairment of INR 8.1 crs

## RIGHTS ISSUE

The Board of Directors has, inter alia, at their meeting held on 30<sup>th</sup> May 2022, considered and approved, subject to receipt of relevant approvals, if and as may be required, to offer, issue and allot such number of equity shares to the existing shareholders of the Company as on the record date to be specified on a Rights Issue basis for an aggregate amount not exceeding INR 200 crores in accordance with the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended, the Companies Act, 2013 and other applicable laws.

Further, the Board appointed Kotak Mahindra Capital Company Limited as the lead manager to the Issue and constituted a Committee of Directors (Rights Issue) to decide the other terms and conditions of the Issue including the record date.

